Palatin Technologies has reported data from its completed Phase II clinical trial and from the Lead In population of the ongoing Phase III MELODY-1 trial of PL9643 for the treatment of dry eye disease (DED).

The data analysis of the MELODY-1 trial was to confirm the hierarchy of the endpoints, optimal endpoints and number of patients for the final Phase III study.

PL9643 was found to have demonstrated effectiveness across multiple clinical signs and reduced symptomatic ocular pain showing its positive affect across multiple regions of the eye.

The magnitude of the absolute difference between PL9643 and vehicle also seems to have exceeded compared to other approved products for several clinical sign and symptom endpoints.

No ocular adverse events were observed in the safety results of Phase II and initial Phase III analysis studies of PL9643 and no patients discontinued usage due to its tolerability issues.

Palatin practicing ophthalmologist and CMO Michael Raizman said: “Based on the safety, ocular tolerability, and efficacy results from the clinical studies, PL9643 may fill an important unmet need in patients with DED.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“PL9643’s novel mechanism of action potentially protects the ocular surface from the damaging effects of inflammation and helps resolve ongoing inflammation.”

The company is continuing patient enrolment for MELODY-1 Phase III study and will announce its topline data in the second half of this year.